TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25352484

Group type: EXPERIMENTAL
Intervention: Endovascular therapy after intravenous r‐tPA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous r‐tPA alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endovascular therapy
Number of subjects: 0
Study: 22143708

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:200,000 adrenaline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine with 1:200,000 adrenaline
Number of subjects: 20
Study: 20540144

Group type: EXPERIMENTAL
Intervention: White Tea (WT)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Green Tea (GT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Water (Control)
Number of subjects: 70
Study: 19099973

Group type: EXPERIMENTAL
Intervention: SCD group (TLR4 expression)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: CHD group (TLR4 expression)
Number of subjects: 75

Group type: COMPARATOR
Intervention: SCD group (A and R values)
Number of subjects: 75

Group type: COMPARATOR
Intervention: CHD group (A value)
Number of subjects: 75

Group type: COMPARATOR
Intervention: CHD group (R value)
Number of subjects: 75
Study: 15948986

Group type: EXPERIMENTAL
Intervention: Air flow at 24 degrees C with SLS 0.5%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Air flow at 43 degrees C with SLS 0.5%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sodium lauryl sulphate (SLS) 0.5% alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Air flow alone
Number of subjects: 20
Study: 12883517

Group type: EXPERIMENTAL
Intervention: Interactive laptop program
Number of subjects: 671
Study: 10504076

Group type: EXPERIMENTAL
Intervention: Intrastromal corneal ring segments (ICRS, Intacs)
Number of subjects: 25
Study: 9065316

Group type: EXPERIMENTAL
Intervention: Tramazoline aerosol (Rhinospray) 0.14 mg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Tramazoline aerosol (Rhinospray) 0.19 mg
Number of subjects: 19
Study: 1683882

Group type: EXPERIMENTAL
Intervention: Noberastine (NOB) 10 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Noberastine (NOB) 20 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Noberastine (NOB) 30 mg
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Noberastine (NOB) 10, 20, and 30 mg
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Noberastine (NOB)
Number of subjects: 250
Study: 6352386

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 31077168

Group type: EXPERIMENTAL
Intervention: Telephone cognitive behavioural therapy (tCBT)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1002
Study: 29690626

Group type: EXPERIMENTAL
Intervention: CGA-HHQ(-) coffee
Number of subjects: 15

Group type: COMPARATOR
Intervention: CGA-HHQ(+) coffee
Number of subjects: 15
Study: 26372416

Group type: EXPERIMENTAL
Intervention: Low-concentration hypochlorous acid nasal irrigation
Number of subjects: 37

Group type: COMPARATOR
Intervention: Isotonic normal saline nasal irrigation
Number of subjects: 37
Study: 24280382

Group type: EXPERIMENTAL
Intervention: Lower body positive pressure (LBPP) for 15 minutes
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (no LBPP)
Number of subjects: 29
Study: 22282432

Group type: EXPERIMENTAL
Intervention: 2 mg intravenous psilocybin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous saline (placebo)
Number of subjects: 10
Study: 20231394

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Amodiaquine-sulfadoxine-pyrimethamine (AQ-SP)
Number of subjects: 559

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 559
Study: 16562406

Group type: EXPERIMENTAL
Intervention: Knowledge of healthy pregnancy habits (assessed through true or false statements)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Median household income
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Knowledge assessment score
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Previous alcohol use by the pregnant woman
Number of subjects: 254
Study: 14526453

Group type: EXPERIMENTAL
Intervention: nCPAP therapy
Number of subjects: 745

Group type: COMPARATOR
Intervention: No nCPAP therapy (untreated group)
Number of subjects: 745
Study: 10898689

Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg single dose in subjects with mild renal impairment (CL(CR) 60 to 80)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg single dose in subjects with moderate renal impairment (CL(CR) 30 to 50)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Stavudine 40 mg single dose in subjects with severe renal impairment (CL(CR) </=20)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Stavudine dosage recommendations for renal impairment (for subjects weighing >/=60 kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Stavudine dosage recommendations for renal impairment (for subjects weighing <60 kg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Stavudine in subjects requiring hemodialysis (study II)
Number of subjects: 32
Study: 8836274

Group type: EXPERIMENTAL
Intervention: Topical lignocaine 40 mg/ml (4 ml, < or = 3 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isotonic saline (4 ml)
Number of subjects: 60
Study: 1417068

Group type: EXPERIMENTAL
Intervention: Fish-oil supplements over a 4-week period
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6239884

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg) + Tetracycline (250 mg) four times daily
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg) + Placebo four times daily
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Tetracycline (250 mg) + Placebo four times daily
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo + Placebo four times daily
Number of subjects: 68
Study: 30664382

Group type: EXPERIMENTAL
Intervention: Dominant leg press training
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nondominant leg press training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Nontraining control
Number of subjects: 42
Study: 27811012

Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 4674

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 4674
Study: 25608747

Group type: COMPARATOR
Intervention: Conventional Stress Echocardiography (CSE)
Number of subjects: 1649

Group type: EXPERIMENTAL
Intervention: Real Time Myocardial Contrast Echocardiography (RTMCE)
Number of subjects: 1649
Study: 23577062

Group type: EXPERIMENTAL
Intervention: Biojector® 2000™ delivery of DNA vaccine (VRC-HIVDNA016-00-VP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Needle and syringe (N/S) delivery of DNA vaccine (VRC-HIVDNA016-00-VP)
Number of subjects: 40
Study: 21950763

Group type: EXPERIMENTAL
Intervention: LVAD patients 3 months after implantation
Number of subjects: 7

Group type: COMPARATOR
Intervention: LVAD patients 1 and 3 months after implantation
Number of subjects: 7
Study: 19327967

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 115
Study: 16686722

Group type: COMPARATOR
Intervention: Solifenacin (5 mg)
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Solifenacin (10 mg)
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Open-label solifenacin treatment
Number of subjects: 1041
Study: 15467097

Group type: EXPERIMENTAL
Intervention: Antioxidant supplement
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11344197

Group type: EXPERIMENTAL
Intervention: human corticotropin-releasing hormone (hCRH)
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ovine corticotropin-releasing hormone (oCRH)
Number of subjects: 8
Study: 9711470

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg once daily
Number of subjects: 33

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg once daily
Number of subjects: 33
Study: 7974297

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 x 8 mg/day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium
Number of subjects: 54
Study: 2690044

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 4442386

Group type: EXPERIMENTAL
Intervention: Preloaded with glucose under 50 dBA noise (Group A)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Preloaded with glucose under 80 dBA noise (Group B)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Not preloaded with glucose under 80 dBA noise (Group C)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Not preloaded with glucose under 50 dBA noise (Group D)
Number of subjects: 32
Study: 29429455

Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention (early rehabilitation including oral sensory and muscle strength training, pressure touching of head, chest, abdomen, extremities, hands, and feet)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Rehabilitation intervention
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group (no early rehabilitation intervention)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study: 28078678

Group type: EXPERIMENTAL
Intervention: Ingenol disoxate 0.037%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ingenol disoxate 0.05%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ingenol disoxate 0.037% and 0.05%
Number of subjects: 0
Study: 23153049

Group type: EXPERIMENTAL
Intervention: Straight injection (SI)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Oblique injection (OI)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Double-plane tunnel injection (DPTI)
Number of subjects: 105
Study: 21509582

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral patient education
Number of subjects: 3541

Group type: COMPARATOR
Intervention: Patient education (control)
Number of subjects: 3541
Study: 18048583

Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (simulated altitude of 4,000-5,500 m)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normobaric normoxia (0-500 m)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia
Number of subjects: 23

Group type: COMPARATOR
Intervention: Normobaric normoxia
Number of subjects: 23
Study: 17066740

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Azathioprine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Plasma exchange
Number of subjects: 40

Group type: COMPARATOR
Intervention: Methylprednisolone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Daily oral cyclophosphamide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pulse cyclophosphamide
Number of subjects: 40
Study: 15815120

Group type: EXPERIMENTAL
Intervention: Beta blocker intervention (n=124)
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: Internal mammary artery grafting intervention (n=114)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Lower volume IMA sites
Number of subjects: 359
Study: 11752510

Group type: EXPERIMENTAL
Intervention: Willow bark extract (Assalix) - 240 mg of salicin daily
Number of subjects: 228

Group type: COMPARATOR
Intervention: Rofecoxib - 12.5 mg daily
Number of subjects: 228
Study: 9436672

Group type: EXPERIMENTAL
Intervention: Small diameter laparoscopy (SDL)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional laparoscopy (CL)
Number of subjects: 37
Study: 8099808

Group type: EXPERIMENTAL
Intervention: Amino acid infusion
Number of subjects: 8

Group type: COMPARATOR
Intervention: Matched control patients
Number of subjects: 8
Study: 3240887

Group type: EXPERIMENTAL
Intervention: 1 g oxytetracycline hydrochloride
Number of subjects: 78

Group type: COMPARATOR
Intervention: Hypertonic saline
Number of subjects: 78

Group type: COMPARATOR
Intervention: Prostaglandin F2 alpha
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Comparison of oxytetracycline hydrochloride with hypertonic saline and prostaglandin F2 alpha
Number of subjects: 78
Study: 31787026

Group type: EXPERIMENTAL
Intervention: Home-based exercise with telemonitoring guidance (30 patients)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Centre-based exercise (30 patients)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (30 patients)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups (Home-based, Centre-based, Control)
Number of subjects: 90
Study: 29898671

Group type: EXPERIMENTAL
Intervention: Sit-to-stand exercise performed at four occasions daily and a protein-rich oral supplement, twice a day for 12 weeks.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 120
Study: 28886394

Group type: EXPERIMENTAL
Intervention: Challenging fat talk vignette
Number of subjects: 283

Group type: COMPARATOR
Intervention: Fat talk vignette
Number of subjects: 283
Study: 25115659

Group type: EXPERIMENTAL
Intervention: Intrusion force of 60 g applied for 21 days on experimental group premolars
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (no force applied)
Number of subjects: 17
Study: 22261129

Group type: EXPERIMENTAL
Intervention: Multiple doses of misoprostol (400 μg every 6 hours, up to 4 doses)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Misoprostol plus oxytocin (initial 600 μg vaginal misoprostol followed by intravenous oxytocin)
Number of subjects: 120
Study: 20309628

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide-containing adjuvant chemotherapy
Number of subjects: 458

Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 458
Study: 17376252

Group type: EXPERIMENTAL
Intervention: Remifentanil-sevoflurane
Number of subjects: 44

Group type: COMPARATOR
Intervention: Remifentanil-propofol
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 15636620

Group type: EXPERIMENTAL
Intervention: Composition of four LAB and four fibers
Number of subjects: 66

Group type: COMPARATOR
Intervention: Fibers only
Number of subjects: 66
Study: 12076912

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation + 20 mg IV doxorubicin (Doxil) 24 hr before ablation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Radiofrequency ablation alone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control lesions (unablated)
Number of subjects: 10
Study: 10388382

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose/P50 placed in increments
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Scotchbond Multi‐Purpose/P50 placed in bulk
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Clearfil Liner Bond 2/Clearfil Ray Posterior placed in bulk
Number of subjects: 48
Study: 8583136

Group type: EXPERIMENTAL
Intervention: Interferon alpha 2b therapy at a dose of 5 MU administered daily until a response was achieved (minimum 6 months or maximum 1 year).
Number of subjects: 37
Study: 2654215

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid cream applied twice daily until clearing was achieved
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo cream applied twice daily until clearing was achieved
Number of subjects: 53
Study: 116053

Group type: EXPERIMENTAL
Intervention: Irrigor (30 to 150 mg daily, administered in tablets, intramuscularly, and intravenously)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Irrigor (administered in courses, single intravenous infusion, double blind method)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Irrigor (administered intramuscularly and intravenously)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Irrigor
Number of subjects: 103
Study: 31090434

Group type: EXPERIMENTAL
Intervention: Xiaoaiping injections (1 dose/day for 10 days) with chemotherapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 140
Study: 28437787

Group type: EXPERIMENTAL
Intervention: 0.6 mL∙kg‐1 of 0.25% levobupivacaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.8 mL∙kg‐1 of 0.25% levobupivacaine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1.0 mL∙kg‐1 of 0.25% levobupivacaine
Number of subjects: 40
Study: 25624379

Group type: EXPERIMENTAL
Intervention: Calories only
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Calories plus minutes
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: Calories plus miles
Number of subjects: 823

Group type: COMPARATOR
Intervention: No labels
Number of subjects: 823
Study: 23618131

Group type: EXPERIMENTAL
Intervention: Surgical reconstruction
Number of subjects: 6
Study: 21323688

Group type: EXPERIMENTAL
Intervention: Dried plums (50 g b.d., fibre=6 gm/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Psyllium (11 g b.d., fibre=6 gm/day)
Number of subjects: 40
Study: 19431054

Group type: EXPERIMENTAL
Intervention: Discharge planning (DP)
Number of subjects: 0
Study: 17518930

Group type: EXPERIMENTAL
Intervention: Stimulation+support
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Support
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Stimulation
Number of subjects: 43
Study: 16636152

Group type: EXPERIMENTAL
Intervention: Community coalitions for asthma control
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Community-wide actions instituted by coalitions
Number of subjects: 7
Study: 12915329

Group type: EXPERIMENTAL
Intervention: Replacement of 10% of energy from saturated fats by trans fatty acids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Replacement of monounsaturated fats by carbohydrates
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trans fats or saturated fats (acute postprandial effects)
Number of subjects: 0
Study: 10618942

Group type: EXPERIMENTAL
Intervention: Esmolol 80 mg i.v.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8552916

Group type: EXPERIMENTAL
Intervention: Exercise training programme
Number of subjects: 10
Study: 1742224

Group type: EXPERIMENTAL
Intervention: Batanopride (0.2 to 6.0 mg/kg)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Batanopride (highest dose group)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Methylprednisolone (250 mg)
Number of subjects: 208
Study: 7178821

Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (CDCA) 1000 mg/day
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ursodeoxycholic acid (UDCA) 1000 mg/day
Number of subjects: 8
Study: 31917897

Group type: EXPERIMENTAL
Intervention: Adaptive training (N = 30)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Met allele carriers (part of genetic study)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active control group (N = 30)
Number of subjects: 60
Study: 30864639

Group type: EXPERIMENTAL
Intervention: α-tocopherol (n=24)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich fraction (n=24)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo (n=23)
Number of subjects: 71
Study: 28167201

Group type: EXPERIMENTAL
Intervention: Iontophoresis-assisted AFL-PDT with 2h incubation (Group A)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional AFL-PDT with 2h incubation (Group B)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional AFL-PDT with 3h incubation (Group C)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 41
Study: 26640796

Group type: EXPERIMENTAL
Intervention: Customized external strap orthosis
Number of subjects: 9
Study: 23143701

Group type: EXPERIMENTAL
Intervention: High frequency/high peak‐to‐peak displacement (HH)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Low frequency/low peak‐to‐peak displacement (LL)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Sham intervention (SHAM)
Number of subjects: 223

Group type: COMPARATOR
Intervention: All groups (HH, LL, SHAM)
Number of subjects: 223
Study: 21457066

Group type: EXPERIMENTAL
Intervention: Insulin glulisine (GLU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin aspart (ASP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin lispro (LIS)
Number of subjects: 0
Study: 18644678

Group type: EXPERIMENTAL
Intervention: Early luteal phase (progesterone high)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ovulatory phase (estrogens high)
Number of subjects: 9
Study: 16943370

Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg (for body weight 20 to 39 kg)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg (for body weight 40 kg or more)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Rizatriptan
Number of subjects: 96
Study: 12631480

Group type: EXPERIMENTAL
Intervention: ADCON-T/N
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no ADCON-T/N)
Number of subjects: 45
Study: 10853305

Group type: EXPERIMENTAL
Intervention: Homozygous sickle cell disease
Number of subjects: 66

Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 66
Study: 9014635

Group type: EXPERIMENTAL
Intervention: Forced group (Fg) with active warming by a forced air system (n = 10)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Passive group (Pg) with reflective insulation on all available skin surface (n = 10)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Reference group (Rg) without a tourniquet (n = 6)
Number of subjects: 26
Study: 1389845

Group type: EXPERIMENTAL
Intervention: Org 9426 (rocuronium) 600 micrograms kg‐1 at 60 s
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Org 9426 (rocuronium) 600 micrograms kg‐1 at 90 s
Number of subjects: 20

Group type: COMPARATOR
Intervention: Suxamethonium 1 mg kg‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Org 9426 (rocuronium)
Number of subjects: 20